» Articles » PMID: 33810564

Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin

Abstract

Eye drops of poorly soluble drugs are frequently formulated as suspensions. Bioavailability of suspended drug depends on the retention and dissolution of drug particles in the tear fluid, but these factors are still poorly understood. We investigated seven ocular indomethacin suspensions (experimental suspensions with two particle sizes and three viscosities, one commercial suspension) in physical and biological tests. The median particle size (d) categories of the experimental suspensions were 0.37-1.33 and 3.12-3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s. Smaller particle size facilitated ocular absorption of indomethacin to the aqueous humor of albino rabbits. In aqueous humor the AUC values of indomethacin suspensions with different particle sizes, but equal viscosity, differed over a 1.5 to 2.3-fold range. Higher viscosity increased ocular absorption 3.4-4.3-fold for the suspensions with similar particle sizes. Overall, the bioavailability range for the suspensions was about 8-fold. Instillation of larger particles resulted in higher tear fluid AUC values of total indomethacin (suspended and dissolved) as compared to application of smaller particles. Despite these tear fluid AUC values of total indomethacin, instillation of the larger particles resulted in smaller AUC levels of indomethacin in the aqueous humor. This suggests that the small particles yielded higher concentrations of dissolved indomethacin in the tear fluid, thereby leading to improved ocular bioavailability. This new conclusion was supported by ocular pharmacokinetic modeling. Both particle size and viscosity have a significant impact on drug concentrations in the tear fluid and ocular drug bioavailability from topical suspensions. Viscosity and particle size are the key players in the complex interplay of drug retention and dissolution in the tear fluid, thereby defining ocular drug absorption and bioequivalence of ocular suspensions.

Citing Articles

Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends.

Kishore A, Mahor A, Singh N, Singh P, Rathore P, Bansal K Bioimpacts. 2025; 15:30224.

PMID: 39963573 PMC: 11830135. DOI: 10.34172/bi.2024.30224.


Mathematical Models of Ocular Drug Delivery.

Sadeghi A, Subrizi A, Del Amo E, Urtti A Invest Ophthalmol Vis Sci. 2024; 65(11):28.

PMID: 39287588 PMC: 11412384. DOI: 10.1167/iovs.65.11.28.


Enhancement of therapeutic efficacy of Brinzolamide for Glaucoma by nanocrystallization and tyloxapol addition.

Masuda S, Yano S, Tadokoro T, Otake H, Nagai N J Pharm Health Care Sci. 2024; 10(1):55.

PMID: 39238043 PMC: 11376053. DOI: 10.1186/s40780-024-00375-5.


Clinical Ocular Exposure Extrapolation for a Complex Ophthalmic Suspension Using Physiologically Based Pharmacokinetic Modeling and Simulation.

Le Merdy M, Spires J, Tan M, Zhao L, Lukacova V Pharmaceutics. 2024; 16(7).

PMID: 39065612 PMC: 11280076. DOI: 10.3390/pharmaceutics16070914.


Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease.

Coco G, Buffon G, Taloni A, Giannaccare G Nanomaterials (Basel). 2024; 14(8).

PMID: 38668163 PMC: 11053557. DOI: 10.3390/nano14080669.


References
1.
Chambers W . Ophthalmic generics--are they really the same?. Ophthalmology. 2012; 119(6):1095-6. DOI: 10.1016/j.ophtha.2012.03.033. View

2.
Huang H, Schoenwald R, LACH J . Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. J Pharm Sci. 1983; 72(11):1272-9. DOI: 10.1002/jps.2600721109. View

3.
Sieg J, Robinson J . Mechanistic studies on transcorneal permeation of fluorometholone. J Pharm Sci. 1981; 70(9):1026-9. DOI: 10.1002/jps.2600700915. View

4.
Ali H, York P, Ali A, Blagden N . Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2010; 149(2):175-81. DOI: 10.1016/j.jconrel.2010.10.007. View

5.
Harigaya Y, Jiang X, Zhang H, Chandaroy P, Stier E, Pan Y . Bioequivalence Study Methods with Pharmacokinetic Endpoints for Topical Ophthalmic Corticosteroid Suspensions and Effects of Subject Demographics. Pharm Res. 2018; 36(1):13. DOI: 10.1007/s11095-018-2537-8. View